On March 19, 2019, the World Intellectual Property Organization (WIPO) published its global intellectual property report 2018.Asian innovators filed more than half of their international patent applications through WIPO for the first time in 2018, with significant growth in China, India and South Korea, the report noted. As a technology-intensive industry, pharmaceutical industry attaches great importance to patent application and intellectual property protection.
In recent years, the size of the global pharmaceutical market has maintained a steady growth, with China, South Korea, India and other emerging markets presenting a rapid growth momentum. With the acceleration of economic globalization, more and more Chinese pharmaceutical companies are entering the European and American markets, and multinational pharmaceutical companies are also increasing their investment in emerging markets.
Due to the different intellectual property policies of different countries, the strategic layout of global intellectual property, the differences of pharmaceutical intellectual property policies of Asia-pacific countries, the patent review process, litigation procedures and Generic drug patent strategy have gradually become the hot spots of the pharmaceutical intellectual property industry.
In this context, the Asia-Pacific Pharma Intellectual Property Leader Summit will be held in Beijing on November 14-15, and will attract more than 400 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.